Dr. Leon Gilead

Certified dermatologist, derm & MOHS surgeon

Search
Publication list:
  1. Histamine and chondroitin sulfate E proteoglycan released by cultured human colonic mucosa: Indication for possible presence of E mast cells. Eliakim, R., Gilead L., Ligumsky M., Okon E., Rachmilewitz D. & E. Razin. Proc.Natl.Acad.Sci.USA, 83, 461-464, 1986.
  2. Human gastric mucosal mast cells are chondroitin sulfate E containing mast cells. Gilead L., Livni N., Eliakim R., Ligumsky M., Fich A., Okon E., Rachmilewitz D. & E. Razin. Immunology, 62, 23-28, 1987.
  3. Cultured human bone marrow-derived mast cells, their similarities to cultured murine E-mast cells. Gilead L., Rahamim E., Ziv I., Or R. & E. Razin. Immunology, 63, 669-675, 1988.
  4. Human interleukin 3: one of the human mast cell growth factors. Gilead L. & E. Razin. FASEB J. Abst., p.A687, 1988.
  5. Synthesis of chondroitin sulfate D and heparin proteoglycans in murine lymph node derived mast cells, the dependency on fibroblasts. Davidson S., Gilead L., Amira M., Ginsburg H. & E. Razin. J.Biol.Chem., 265, 12324-12330, 1990.
  6. Fibroblast induced heparin synthesis in chondroitin sulfate E containing, human bone marrow derived, mast cells. Gilead L., Bibi O. & E. Razin. Blood, 76, 1188-1195, 1990.
  7. A look at gray hair. Vardy DA, Marcus B-S, Gilead L, Klapholz L, Lichtenstein DA, Rashkovsky I, Klaus SN,. J.Geriat.Dermatol., 1993, 1(1):22-27.
  8. Mammary calcifications in Weber-Christian disease. Leibovici V, Gilead L, Gimmon Z, Lax E, 1994, Eur.J.Radiol., 18(1):70-1.
  9. Treatment of vulvar lichen sclerosus in the elderly - an update. Elhalal U., Gilead L., Vardy D.A., Ben-Shahar I., Anteby S.O., Schenkar J.G., 1995, Obstet.Gynecol.Surv., 50(2):155-62.
  10. Tefillin Dermatitis (A phylacteric phenomenon). Gilead L., Vardy D.A., Schamroth J., 1995, J.Am.Acad. Dermatol., 32:812-3.
  11. Acro-angiodermatitis: review of the literature and Report of a case. Rashkovsky I., Gilead L., Shamroth J.,  Leibovici V., ACTA Dermatol. Venereol., 1995, 75:475..
  12. Immunosuppression-induced Porokeratosis of Mibelli: complete regression of lesions upon cessation of immunosuppressive therapy. Gilead L., Guberman D., Zlotogorsky A., Vardy D.A., Klaus S.N., J.Eur.Acad. Dermatol.Venereol., 1995, 5:170-172.
  13. Chronic radiodermatitis following cardiac catheterization. Lichtenstein D.A., Klapholz L., Vardy D., Leidhter I., Mosseri M., Klaus S.N., Gilead L.T., Arch Dermatol, 1996; 132:663-667.
  14. Fever, Convulsions and Coma in Scleromyxedema: a “dermato-neuro syndrome”. River Y., Levi I., Gilead L., Orbach H., Almog Y., Neurology, 1996, 46:1778-9.
  15. Familial pityriasis rotunda [letter] Guberman D., Lichtenstein D.A., Gilead L., Vardy D.A., Klaus S.N., Acta.Derm.Venereol. 1997 Mar; 77(2): 162.
  16. Porokeratosis of Mibelli. Overview and review of the literature. Schamroth J.M., Zlotogorski A., Gilead L., Acta.Derm.Venereol. 1997 May; 77(3): 207-13.
  17. Salicilism following topical application of 20% salicilic acid for psoriasis. Jabarah A., Gilead L., Zlotogorski A., J. Eur. Acad. Dermatol. Venereol., 1997, 8:41-2.
  18. Terra firma forme dermatosis. Raveh T, Gilead LT, Wexler MR, Ann Plast Surg 1997 Nov;39(5):542-545
  19. Chronic unilateral leg inflammation in a young man. Guberman D, Reinus C, Gilead L, Goldenhersh MA, Arch Dermatol 1998 Jun;134(6):743
  20. South American cutaneous leishmaniasis: report of ten cases in Israeli travelers. Zlotogorski A, Gilead L, Jonas F, Horev L, Klaus SN, Eur Acad Dermatol Venereol 1998 Jul;11(1):32-36
  21. Skin calcinosis following allogenic bone marrow transplantation in an acute lymphoblastic leukaemia patient. Guberman D, Gilead LT, Nagler A Acta Derm Venereol. 1999 Jul;79(4):324-5.
  22. Maggot therapy for the treatment of intractable wounds. Mumcuoglu KY, Ingber A, Gilead L, Stessman J, Friedmann R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I, Int J Dermatol 1999 Aug;38(8):623-7.
  23. Bullous Erysipellas - A retrospective study of 26 cases, Guberman D., Gilead L., Zlotogorski A., Schamroth J., J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):733-7.
  24. Maggot therapy for the treatment of diabetic foot ulcers. Mumcuoglu KY, Ingber A, Gilead L, Stessman J, Friedmann R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I, Diabetes Care 1998 Nov;21(11):2030-1
  25. Maggot therapy for the treatment of intractable wounds. Mumcuoglu KY, Ingber A, Gilead L, Stessman J, Friedmann R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I. Int J Dermatol. 1999 Aug; 38(8): 623-7.
  26. Maggot debridement therapy in outpatients. Sherman RA, Sherman J, Gilead L, Lipo M, Mumcuoglu KY. Arch Phys Med Rehabil. 2001 Sep; 82(9:1226-9.
  27. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Vardy D, Barenholz Y, Naftoliev N, Klaus S, Gilead L, Frankenburg S. Trans R Soc Trop Med Hyg. 2001 Mar-Apr; 95(2): 184-6.
  28. Mediterranean spotted fever in Israel: a tick-borne disease. Mumcuoglu KY, Keysary A, Gilead L. Isr Med Assoc J. 2002 Jan; 4(1): 44-9.
  29. Treatment of cutaneous leishmaniasis--an update Vardy DA, Gilead L, Frankenburg S. Harefuah. 2002 Jan; 141(1): 70-5, 125, 124.
  30. Fatal hemophagocytic syndrome in a patient with panniculitis-like T-cell lymphoma and no clinical evidence of disease. Goldschmidt N, Amir G, Krieger M, Gilead L, Paltiel O., Leuk Lymphoma. 2003 Oct; 44(10): 1803-6.
  31. Diagnostic performance and retention of acquired skills after dermatology elective. Enk CD, Gilead L, Smolovich I, Cohen R. Int J Dermatol. 2003 Oct; 42(10): 812-5.
  32. Intralesional therapy of oral leishmaniasis. Czerniski R, Gilead L, Abedelmajeed N, Markitziu A. Int J Dermatol. 2003 Sep; 42(9): 752-4.
  33. A nonsense mutation in the desmoglein 1 gene underlies striate keratoderma. Kljuic A, Gilead L, Martinez-Mir A, Frank J, Christiano AM, Zlotogorski A. Exp Dermatol. 2003 Aug; 12(4): 523-7.
  34. Combined therapy for pyoderma gangrenosum. Rozin AP, Balbir-Gurman A, Gilead L, Slodownik D., Ann Rheum Dis. 2004 Jul;63(7):888-9
  35. Plantar ulcers and eyebrow-hair paucity. Elinav H, Palladas L, Applbaum YH, Gilead L, Moses AE, Cohen-Poradosu R. Clin Infect Dis. 2006 Mar 1;42(5):684-5, 722-4.
  36. Recommendations for the treatment of scabies infestations in Israel. Mumcuoglu KY, Gilead LT, Isr Med Assoc J. 2006 Mar;8(3):196-9.
  37. The use of hybrid radiofrequency device for the treatment of rhytides and lax skin. Friedman DJ, Gilead LT, Dermatol Surg. 2007 May;33(5):543-51.
  38. Treatment of scabies infestations. Mumcuoglu KY, Gilead L. Parasite. 2008 Sep;15(3):248-51.
  39. [Physicians' knowledge in Israel on the biology and control of head lice] Mumcuoglu KY, Mumcuoglu M, Danilevich M, Gilead L., Harefuah. 2008 Oct;147(10):754-7, 840. Hebrew.
  40. Tropism of herpes simplex virus type 1 to nonmelanoma skin cancers. Hochberg M, Kunicher N, Gilead L, Maly A, Falk H, Ingber A, Panet A. Br J Dermatol. 2011 Feb;164(2):273-81.
  41. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Cohen O, Trau H, Aharon-Peretz J, Milo R, Schwartz M, Huberman M, Gilead L, Barchana M, Liphshiz I, Fitzer-Attas C, Giladi N. J Neural Transm. 2011 Feb 5. [Epub ahead of print]
  42. Polyhydroxylated fatty alcohols derived from avocado suppress inflammatory response and provide non-sunscreen protection against UV-induced damage in skin cells. Rosenblat G, Meretski S, Segal J, Tarshis M, Schroeder A, Zanin-Zhorov A, Gilead L. Ingber A, Hochberg M. Arch Dermatol Res. 2011 May;303(4):239-46.
  43. The use of maggot debridement therapy in the treatment of chronic wounds in hospitalized and ambulatory patients. Gilead L. Mumcuoglu KY  Ingber A. journal of wound care. 2012 Feb;21,2:78-85
 

Dermatology is one of widest and most diverse areas of medicine, and like many other modern medical fields, It also was subjected in the last decades to fundamental changes with the emergence of new research areas closely followed by new medication and treatments. A dermatologist knows more than 3000 disease conditions, their dianostic criteria and treatments.
Dr. Gilead is one of the leading dermatologists in Israel and is being continuously updated in these innovations. For the convenience of users, there are diverse information leaflets written by Dr. Gilead, dealing with Dr. Gilead's special interest areas as well as description of the treatments performed in the clinic and in operating rooms in the hospitals he is working with.

The clinic is centrally located in Jerusalem, Designed & built for the convenience of the patients in a manner allowing for complete privacy in the treatment rooms. 'Clalit Mushlam' 'Macaby Magen Zahav (Gold Shield)' 'Leumit complementary services (Shaban)' insurance holders are admitted through regular arrangements and reception is also for private patients with other kinds of medical insurance.

Reception hours are on Sundays, Tuesdays & Wednesdays between 17:00-20:00 (reception is only with a preset appointment). Clinic days & hours may be changed on short notice (registered patients shall be informed in advance if possible).
There is a 24/7 computerized answering service for arranging appointments at 053-5633033

Dr. Leon Gilead was born in Haifa, in 1960. He is married and a father of 4.

He is a graduate of the Hadassah & Hebrew University Faculty of Medicine, holding an MD and a PhD in biochemistry. He studies Dermatology in the Hadassah University Medical Center's Dermatology department and on 2004 attended a MOHS surgery course & preceptorship in Sun-Diego, California.
Formerly a senior physician and a unit head at the Hadassah University Medical Center's Dermatology department, head of the Dermato & MOHS Surgery Clinic and The Israeli Hansen's disease center.
He is a consultant to the Psoriasis patient organization In Israel as well as HMO's and to private medical insurance companies.
טלפון:  02-5633033     |     פקס:  02-5633000     |     דוא"ל:  5633033f@gmail.com     |     כתובת:  עמק רפאים 43ב', קומה ראשונה

About

Further Info

The Clinic